GlobeNewswire·Jan 6, 2026, 11:15 PM ET

Praxis Precision Medicines, Inc. Announces Pricing of $575 Million Public Offering

Praxis Precision Medicines, Inc. priced an underwritten public offering of 2,212,000 shares of common stock at $260.00 per share.
The gross proceeds from the offering are expected to be approximately $575 million before deducting underwriting discounts, commissions, and estimated offering expenses.
Praxis granted underwriters a 30-day option to purchase up to 331,800 additional shares at the public offering price less underwriting discounts.
The offering is expected to close on or about January 8, 2026, subject to market conditions and customary closing conditions.
Piper Sandler, TD Cowen, Guggenheim Securities, & Truist Securities are acting as joint book-running managers for the offering.
The offering was made pursuant to a shelf registration statement on Form S-3ASR filed with the SEC on December 23, 2024.
A preliminary prospectus supplement was filed with the SEC on January 6, 2026, with the final terms to be disclosed in a subsequent final prospectus supplement.